451 related articles for article (PubMed ID: 28630189)
1.
McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
[TBL] [Abstract][Full Text] [Related]
2. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
Saravolatz LD; Pawlak JM; Wegner C
J Antimicrob Chemother; 2020 Sep; 75(9):2605-2608. PubMed ID: 32542310
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
[TBL] [Abstract][Full Text] [Related]
4.
Pfaller MA; Sader HS; Rhomberg PR; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167542
[TBL] [Abstract][Full Text] [Related]
5. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019).
Shortridge D; Pfaller MA; Streit JM; Flamm RK
J Glob Antimicrob Resist; 2020 Dec; 23():278-283. PubMed ID: 33068780
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
8.
Scangarella-Oman NE; Ingraham KA; Tiffany CA; Tomsho L; Van Horn SF; Mayhew DN; Perry CR; Ashton TC; Dumont EF; Huang J; Brown JR; Miller LA
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818823
[TBL] [Abstract][Full Text] [Related]
9. Delafloxacin
Pfaller MA; Flamm RK; McCurdy SP; Pillar CM; Shortridge D; Jones RN
J Clin Microbiol; 2018 Aug; 56(8):. PubMed ID: 29848564
[TBL] [Abstract][Full Text] [Related]
10.
Kong Y; Li C; Li G; Yang T; Draz MS; Xie X; Zhang J; Ruan Z
Microbiol Spectr; 2022 Jun; 10(3):e0009922. PubMed ID: 35532225
[TBL] [Abstract][Full Text] [Related]
11. High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus.
de la Rosa JMO; Fernández MA; Rodríguez-Villodres Á; Casimiro-Soriguer CS; Cisneros JM; Lepe JA
Int J Antimicrob Agents; 2023 Jun; 61(6):106795. PubMed ID: 36965675
[TBL] [Abstract][Full Text] [Related]
12. In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone.
Fan KC; Lin J; Yannuzzi NA; Al-Khersan H; Patel NA; Maestre-Mesa J; Zaidi M; Miller D; Flynn HW
J Ophthalmic Inflamm Infect; 2020 Feb; 10(1):9. PubMed ID: 32103368
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Giordano PA; Pogue JM; Cammarata S
Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
16. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
17. The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
Huang DB; Charrier C; Le Bras C; Hawser S; Noviello S
J Med Microbiol; 2019 Jun; 68(6):898-902. PubMed ID: 31050628
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
20. Delafloxacin (Baxdela)--a new fluoroquinolone antibiotic.
Med Lett Drugs Ther; 2018 Mar; 60(1543):49-51. PubMed ID: 29635263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
